Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.9%

1 terminated/withdrawn out of 17 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

53%

9 trials in Phase 3/4

Results Transparency

7%

1 of 14 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
8(47.1%)
Phase 1
4(23.5%)
Phase 2
3(17.6%)
Phase 4
1(5.9%)
N/A
1(5.9%)
17Total
Phase 3(8)
Phase 1(4)
Phase 2(3)
Phase 4(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT04763265Phase 2Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Role: collaborator

NCT06216418Not ApplicableUnknown

Evaluate the Safety and Efficacy of 'BRFS-18G-S100WH' as Compared to 'MINT Lift FINE+' in Subject With Nasolabial Folds

Role: lead

NCT05801146Phase 3Unknown

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

Role: lead

NCT04012099Phase 2Terminated

the Hypertrophic Scar Prevention of BMT101.

Role: lead

NCT04944953Phase 1Completed

To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

Role: lead

NCT05380154Phase 3Completed

Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.

Role: lead

NCT04171258Phase 1Completed

Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia

Role: lead

NCT01791920Phase 3Completed

To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

Role: lead

NCT03408236Phase 3Completed

Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

Role: lead

NCT04186442Phase 1Completed

Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder

Role: lead

NCT04443244Phase 2Completed

Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy

Role: lead

NCT03641950Phase 4Completed

The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.

Role: lead

NCT03133130Phase 1Completed

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Role: lead

NCT02833532Phase 3Completed

A Multi-center, Randomized, Subject Blind, Active Controlled Design Clinical Study to Evaluate the Efficacy and Safety of Volus as Compared to PowerFill® for Temporary Penile Enhancement

Role: lead

NCT01787344Phase 3Completed

Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy

Role: lead

NCT01915459Phase 3Completed

Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity

Role: lead

NCT01791881Phase 3Completed

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm

Role: lead

All 17 trials loaded